Twist Bioscience Corporation

Twist Bioscience Corporation

TWSTยทNASDAQ

$76.92

+6.8%
HealthcareMedical - Diagnostics & Research

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$4.79B
EPS-1.3000
P/E Ratio-59.17
Earnings Date08/03/2026
3Y-33.0%
5Y+61.0%
10Y+739.0%
3Y-2.0%
5Y+170.0%
10Y+10.0%
3Y-40.0%
5Y+41.0%
10Y-717.0%
twst

Twist Bioscience Corporation Funding & Solvency Profile

TWST ยท NASDAQ
Cash & Cash Equivalents183.05M
Net Receivables57.02M
Inventory28.31M
Other Current Assets0.00
Total Current Assets333 M
Property, Plant & Equipment151.66M
Goodwill & Intangible Assets95.62M
Long-Term Investments54.34M
Other Non-Current Assets7.28M
Total Non-Current Assets213 M
Total Assets
641.86M

Financial Health Analysis

Current Ratio

3.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.36x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

242 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

52% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Twist Bioscience Corporation Balance Sheet

TWST โ€ข NASDAQ

Twist Bioscience Corporation Balance SheetSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
ASSETS
CURRENT ASSETS
183M
226.3M
286.5M
378.7M
465.8M
93.7M
46.7M
80.8M
31.2M
28.6M
49.4M
50.1M
49.9M
126.3M
12M
196.3M
91.4M
0.0
31M
27.3M
232.4M
276.4M
336.4M
505M
477.9M
290M
138.1M
80.8M
62.2M
55.9M
57M
34.9M
44.1M
40.3M
28.5M
26.4M
12.1M
5.4M
2.3M
723K
57M
34.9M
44.1M
40.1M
26.2M
25.4M
10.8M
5.3M
2.2M
664K
0.0
0.0
0.0
234K
2.3M
951K
1.3M
75K
109K
59K
28.3M
24.1M
32.1M
39.3M
31.8M
12.3M
7.3M
6M
1.8M
1.2M
15.2M
0.0
0.0
11.9M
8.3M
0.0
2.6M
3.3M
1.5M
1.2M
0.0
11.4M
11.7M
0.0
0.0
6.2M
0.0
3.5M
0.0
0.0
333M
346.8M
424.3M
596.5M
546.5M
334.9M
160.1M
95.7M
67.9M
59M
NON-CURRENT ASSETS
151.7M
161.3M
203.4M
214.4M
105.7M
59.2M
20.8M
12.3M
14.8M
14.6M
82.2M
85.8M
85.8M
85.8M
22.4M
1.1M
1.1M
1.1M
1.1M
1.1M
13.4M
14.5M
54.5M
59.7M
18.3M
307K
508K
712K
920K
1.1M
95.6M
100.3M
140.3M
145.5M
40.7M
1.4M
1.6M
1.9M
2.1M
2.3M
54.3M
0.0
0.0
0.0
0.0
579K
579K
579K
202K
322K
0.0
0.0
0.0
0.0
0.0
-579K
-579K
-579K
-202K
-322K
7.3M
5.9M
8.5M
5M
9.2M
3.4M
4.4M
5.9M
896K
536K
308.9M
267.5M
352.1M
364.9M
155.6M
64M
26.9M
20.1M
17.8M
17.4M
0.0
0.0
0.0
-1K
0.0
0.0
0.0
0.0
0.0
0.0
641.9M
614.3M
776.4M
961.4M
702.1M
398.9M
187M
115.8M
85.7M
76.5M
LIABILITIES
CURRENT LIABILITIES
15.6M
4.4M
14.1M
23.8M
17.3M
4.8M
9.8M
7.5M
2.8M
2.3M
11.1M
1.6M
14.1M
20.1M
14.9M
4.8M
9.8M
7.5M
2.8M
2.3M
4.5M
2.7M
0.0
3.7M
2.4M
0.0
0.0
0.0
0.0
0.0
31.3M
15.1M
25.8M
10.2M
6.4M
14.9M
16.4M
5.4M
3.5M
4.6M
13.8M
0.0
0.0
0.0
1.6M
9.7M
3.3M
2.5M
0.0
1.4M
0.0
14.8M
14.9M
13.6M
8.2M
6.4M
0.0
0.0
0.0
0.0
0.0
2.7M
4.4M
3.7M
2.4M
719K
0.0
0.0
0.0
0.0
6.9M
2.1M
0.0
3.5M
1.1M
18.8M
16.4M
7.6M
0.0
4.6M
23.8M
34.6M
18.6M
39.6M
28.4M
103K
817K
3.1M
3.2M
353K
91.4M
71M
73.3M
90.7M
63.1M
36M
30.4M
18.5M
9.5M
8.7M
NON-CURRENT LIABILITIES
61.8M
0.0
0.0
0.0
0.0
1.4M
4.4M
7.2M
9.2M
9.8M
-46M
407K
475K
60K
5.1M
351K
158K
291.5M
200.4M
134.6M
77.5M
70.6M
79.6M
81.3M
58.2M
26.6M
4.6M
298.7M
209.5M
144.4M
61.8M
85M
94.1M
94.9M
61.4M
31.2M
0.0
0.0
0.0
0.0
168.9M
141.6M
153M
172M
121.3M
62.6M
34.9M
317.2M
219M
153.1M
SHAREHOLDERS' EQUITY
0.0
0.0
0.0
0.0
0.0
0.0
187M
631K
199.6M
134M
1.8B
1.7B
1.7B
1.6B
1.2B
794.6M
470.4M
9.3M
6.2M
3.7M
-1.3B
-1.2B
-1B
-828.4M
-610.6M
-458.5M
-318.5M
-210.9M
-139.6M
-80.3M
-627K
-522K
-756K
-1.8M
546K
87K
181K
87K
33K
9K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-631K
-199.6M
-134M
473M
472.7M
623.4M
789.4M
580.8M
336.3M
152.1M
-201.4M
-133.4M
-76.6M
473M
472.7M
623.4M
789.4M
580.8M
336.3M
152.1M
-201.4M
-133.4M
-76.6M
SUMMARY
641.9M
614.3M
776.4M
961.4M
702.1M
398.9M
187M
115.8M
85.7M
76.5M
103.7M
50.1M
49.9M
126.3M
12M
196.3M
92M
579K
31.2M
27.6M
137.3M
85M
94.1M
94.9M
62.9M
36M
7.7M
9.7M
9.2M
11.2M
-45.7M
-141.3M
-192.4M
-283.8M
-402.9M
-57.7M
-39M
-71M
-22.1M
-17.4M
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925
60,360,925

SEC Filings

TWST - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 04, 2026
May 04, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 04, 2026
March 31, 2026
2026
10-Q/A

10-Q/A 2025 Q4 (Amended)

Q4

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 17, 2026
February 11, 2026
2026
8-K

8-K 2026

N/A

February 06, 2026
February 05, 2026
2026
10-Q

10-Q 2025 Q4

Q4

February 02, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 02, 2026
February 02, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
DEF 14A

DEF 14A 2026

N/A

January 06, 2026
February 05, 2026
2026
10-K

10-K 2025 FY

FY

November 17, 2025
September 30, 2025
2025
Showing 1 to 10 of 125 filings